Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA: 688192)
China
· Delayed Price · Currency is CNY 46.18
-1.56 (-3.27%)
Nov 13, 2024, 9:30 AM CST
Dizal (Jiangsu) Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Operating Revenue | 389.64 | 91.29 | - | 10.29 | - | 41.02 | Upgrade
|
| Other Revenue | - | - | - | - | 27.76 | - | Upgrade
|
| Revenue | 389.64 | 91.29 | - | 10.29 | 27.76 | 41.02 | Upgrade
|
| Revenue Growth (YoY) | 871.61% | - | - | -62.95% | -32.32% | 4.05% | Upgrade
|
| Cost of Revenue | 13.65 | 7.66 | 3.65 | 12.93 | 26.56 | 35.83 | Upgrade
|
| Gross Profit | 375.99 | 83.63 | -3.65 | -2.65 | 1.2 | 5.19 | Upgrade
|
| Selling, General & Admin | 562.79 | 437.55 | 128.44 | 87.95 | 340.43 | 46.87 | Upgrade
|
| Research & Development | 789.73 | 801.15 | 660.87 | 583.67 | 423.94 | 408.93 | Upgrade
|
| Other Operating Expenses | -13.5 | -0.27 | -0.39 | 0.1 | 0.49 | 0.17 | Upgrade
|
| Operating Expenses | 1,339 | 1,239 | 788.9 | 671.73 | 764.84 | 455.94 | Upgrade
|
| Operating Income | -963.43 | -1,155 | -792.55 | -674.37 | -763.65 | -450.75 | Upgrade
|
| Interest Expense | -3.08 | -7.57 | -4.34 | -3.07 | - | - | Upgrade
|
| Interest & Investment Income | 0.77 | 3.64 | 2.53 | 3.65 | 3.89 | 2.82 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.45 | -1.45 | 10.1 | -6.45 | -28.9 | 1.33 | Upgrade
|
| Other Non Operating Income (Expenses) | -15.03 | -0.04 | -0.03 | -0.08 | -0.33 | -0.02 | Upgrade
|
| EBT Excluding Unusual Items | -982.22 | -1,161 | -784.3 | -680.32 | -788.99 | -446.61 | Upgrade
|
| Gain (Loss) on Sale of Investments | 15.14 | 22.52 | 42.16 | 0.97 | 0.29 | 0.45 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.01 | 0.02 | - | 198.82 | - | Upgrade
|
| Other Unusual Items | 38.74 | 30.5 | 6.39 | 9.47 | 3.29 | 0.42 | Upgrade
|
| Pretax Income | -928.34 | -1,108 | -735.74 | -669.88 | -586.58 | -445.75 | Upgrade
|
| Income Tax Expense | 0.07 | 0.1 | 0.26 | - | 0.03 | 0 | Upgrade
|
| Net Income | -837.22 | -1,108 | -736 | -669.88 | -586.61 | -445.75 | Upgrade
|
| Net Income to Common | -837.22 | -1,108 | -736 | -669.88 | -586.61 | -445.75 | Upgrade
|
| Shares Outstanding (Basic) | 411 | 407 | 404 | 360 | 360 | - | Upgrade
|
| Shares Outstanding (Diluted) | 411 | 407 | 404 | 360 | 360 | - | Upgrade
|
| Shares Change (YoY) | 1.03% | 0.70% | 12.29% | 0.07% | - | - | Upgrade
|
| EPS (Basic) | -2.04 | -2.72 | -1.82 | -1.86 | -1.63 | - | Upgrade
|
| EPS (Diluted) | -2.04 | -2.72 | -1.82 | -1.86 | -1.63 | - | Upgrade
|
| Free Cash Flow | -861.98 | -1,000 | -677.15 | -501.26 | -621.75 | -379.45 | Upgrade
|
| Free Cash Flow Per Share | -2.10 | -2.46 | -1.67 | -1.39 | -1.73 | - | Upgrade
|
| Gross Margin | 96.50% | 91.61% | - | -25.72% | 4.31% | 12.66% | Upgrade
|
| Operating Margin | -247.26% | -1265.43% | - | -6556.55% | -2750.82% | -1098.91% | Upgrade
|
| Profit Margin | -214.87% | -1213.42% | - | -6512.85% | -2113.09% | -1086.74% | Upgrade
|
| Free Cash Flow Margin | -221.23% | -1095.44% | - | -4873.51% | -2239.65% | -925.10% | Upgrade
|
| EBITDA | -924.25 | -1,116 | -753.85 | -636.97 | -733.83 | -427.43 | Upgrade
|
| D&A For EBITDA | 39.18 | 38.98 | 38.7 | 37.4 | 29.82 | 23.32 | Upgrade
|
| EBIT | -963.43 | -1,155 | -792.55 | -674.37 | -763.65 | -450.75 | Upgrade
|
| Revenue as Reported | 51.19 | 91.29 | - | 10.29 | 27.76 | - | Upgrade
|
| Advertising Expenses | - | 24.38 | 1.94 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.